Skip to main content

Transgenomic's Q1 Revenue Rises 21 Percent; Swings to Profit

NEW YORK (GenomeWeb News) – Transgenomic yesterday reported a 21.2 percent increase in first-quarter revenues and a profit versus a loss a year earlier.
 
The Omaha, Neb.-based cancer genetic test provider said that it brought in revenues of $6.3 million for the three-month period ended March 31, compared to revenues of $5.2 million for the first quarter of 2007.
 
Transgenomic President and CEO Craig Tuttle said that the firm’s instrument and consumables sales “achieved expectations and our two laboratory services business performed very well in the quarter.” The firm’s molecular clinical reference lab had revenues of $500,000, up 74 percent from the comparable period in 2007, and its pharmacogenomics research services lab had revenues of $467,000, which was nearly 500 percent higher than a year earlier.
 
Transgenomic posted a profit of $122,000, or $.00 per share, compared to a net loss of $1.2 million, or $.02 per share, in the first quarter of 2007. It was the second straight quarter of profitability for the firm.
 
Its R&D spending dropped nearly by half to $572,000 from $1.1 million, while its SG&A costs were flat at $3 million.
 
Transgenomic finished the quarter with $5.8 million in cash and cash equivalents.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.